Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer
BACKGROUND: Correlations between development of hand-foot syndrome (HFS) and efficacy in patients receiving capecitabine (CAP)-containing therapy are reported in the literature. We explored the relationship between HFS and efficacy in patients receiving CAP plus bevacizumab (BEV) in the TURANDOT ran...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2016
|
| Sorozat: | BRITISH JOURNAL OF CANCER
114 |
| doi: | 10.1038/bjc.2015.419 |
| mtmt: | 2992639 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/11867 |
| LEADER | 02882nab a2200313 i 4500 | ||
|---|---|---|---|
| 001 | publ11867 | ||
| 005 | 20200117150004.0 | ||
| 008 | 170830s2016 hu o 0|| zxx d | ||
| 022 | |a 0007-0920 | ||
| 024 | 7 | |a 10.1038/bjc.2015.419 |2 doi | |
| 024 | 7 | |a 2992639 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a zxx | ||
| 100 | 1 | |a Zielinski Christoph | |
| 245 | 1 | 0 | |a Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer |h [elektronikus dokumentum] / |c Zielinski Christoph |
| 260 | |c 2016 | ||
| 300 | |a 163-170 | ||
| 490 | 0 | |a BRITISH JOURNAL OF CANCER |v 114 | |
| 520 | 3 | |a BACKGROUND: Correlations between development of hand-foot syndrome (HFS) and efficacy in patients receiving capecitabine (CAP)-containing therapy are reported in the literature. We explored the relationship between HFS and efficacy in patients receiving CAP plus bevacizumab (BEV) in the TURANDOT randomised phase III trial. METHODS: Patients with HER2-negative locally recurrent/metastatic breast cancer (LR/mBC) who had received no prior chemotherapy for LR/mBC were randomised to BEV plus paclitaxel or BEV-CAP until disease progression or unacceptable toxicity. This analysis included patients randomised to BEV-CAP who received 1 CAP dose. Potential associations between HFS and both overall survival (OS; primary end point) and progression-free survival (PFS; secondary end point) were explored using Cox proportional hazards analyses with HFS as a time-dependent covariate (to avoid overestimating the effect of HFS on efficacy). Landmark analyses were also performed. RESULTS: Among 277 patients treated with BEV-CAP, 154 (56%) developed HFS. In multivariate analyses, risk of progression or death was reduced by 44% after the occurrence of HFS; risk of death was reduced by 56%. The magnitude of effect on OS increased with increasing HFS grade. In patients developing HFS within the first 3 months, median PFS from the 3-month landmark was 10.0 months vs 6.2 months in patients without HFS. Two-year OS rates were 63% and 44%, respectively. CONCLUSIONS: This exploratory analysis indicates that HFS occurrence is a strong predictor of prolonged PFS and OS in patients receiving BEV-CAP for LR/mBC. Early appearance of HFS may help motivate patients to continue therapy.British Journal of Cancer advance online publication, 10 December 2015; doi:10.1038/bjc.2015.419 www.bjcancer.com. | |
| 700 | 0 | 1 | |a Láng István |e aut |
| 700 | 0 | 1 | |a Beslija Semir |e aut |
| 700 | 0 | 1 | |a Kahán Zsuzsanna |e aut |
| 700 | 0 | 1 | |a Inbar Moshe J. |e aut |
| 700 | 0 | 1 | |a Stemmer Salomon M. |e aut |
| 700 | 0 | 1 | |a Anghel Rodica |e aut |
| 700 | 0 | 1 | |a Vrbanec Damir |e aut |
| 700 | 0 | 1 | |a Messinger Diethelm |e aut |
| 700 | 0 | 1 | |a Brodowicz Thomas |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/11867/1/bjc2015419a.pdf |z Dokumentum-elérés |